13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001587114
Total reported value
$2.1B
$2.1B
44 檔
47.1%
The Q1 2025 SEC filing reveals that EcoR1 Capital, LLC held a total portfolio value of $2.1B, covering 44 public equity positions.
In Q1 2025, EcoR1 Capital, LLC displayed an active expansion posture, initiating 44 new positions and adding to 0 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including APLSUSD, JAZZ, ZYME) accounted for 47.1% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 15.43% | — | +0.04% | |
| 2 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 12.57% | -13.69% | EXIT | |
| 3 | ZYME | Zymeworks Inc | Stock-Other | 12.19% | +4.78% | +14.85% | |
| 4 | ANAB | Anaptysbio Inc | Stock-Other | 8.69% | +7.31% | +0.08% | |
| 5 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 8.53% | -6.61% | EXIT | |
| 6 | PRTA | Prothena Corporation plc | Stock-Other | 8.50% | — | — | |
| 7 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 4.89% | — | +67.84% | |
| 8 | XNCR | Xencor Inc | Stock-Other | 3.88% | -1.12% | EXIT | |
| 9 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 2.80% | +0.88% | — | |
| 10 | QURE | uniQure N.V. | Stock-Other | 2.59% | — | +8.96% | |
| 11 | JANX | Janux Therapeutics Inc | Stock-Other | 2.35% | — | — | |
| 12 | IMNM | Immunome Inc | Stock-Other | 1.63% | — | +5.16% | |
| 13 | ETON | Eton Pharmaceuticals Inc | Stock-Other | 1.53% | +1.55% | +0.44% | |
| 14 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.47% | — | — | |
| 15 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.13% | -0.08% | — | |
| 16 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.06% | — | — | |
| 17 | KURA | Kura Oncology Inc | Stock-Other | 1.03% | — | -25.78% | |
| 18 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.98% | — | +10.13% | |
| 19 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.98% | — | — | |
| 20 | NGNE | Neurogene Inc | Stock-Other | 0.88% | +0.85% | — | |
| 21 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.86% | — | — | |
| 22 | VYGR | Voyager Therapeutics Inc | Stock-Other | 0.79% | — | — | |
| 23 | BEAM | Beam Therapeutics Inc | Stock-Other | 0.61% | — | — | |
| 24 | MBX | Mbx Biosciences Inc | Stock-Other | 0.55% | +0.06% | — | |
| 25 | DNA | Ginkgo Bioworks Holdings Inc | Stock-Other | 0.49% | — | -16.12% | |
| 26 | REPL | Replimune Group Inc | Stock-Other | 0.49% | -0.32% | EXIT | |
| 27 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.46% | — | — | |
| 28 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 0.41% | — | — | |
| 29 | ✓ | Verve Therapeutics Inc | Stock-Other | 0.34% | — | — | |
| 30 | ADAPY | Adaptimmune Therapeutics-adr | Stock-Other | 0.32% | — | — | |
| 31 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 0.23% | +0.31% | — | |
| 32 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 0.22% | — | +503.04% | |
| 33 | ATRA | Atara Biotherapeutics Inc | Stock-Other | 0.20% | +0.85% | +7.71% | |
| 34 | SLDB | Solid Biosciences Inc | Stock-Other | 0.16% | — | — | |
| 35 | KROS | Keros Therapeutics Inc | Stock-Other | 0.11% | — | — | |
| 36 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.10% | — | — | |
| 37 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.10% | -0.17% | — | |
| 38 | KLRS | Kalaris Therapeutics Inc | Stock-Other | 0.10% | — | — | |
| 39 | PRME | Prime Medicine Inc | Stock-Other | 0.08% | — | — | |
| 40 | ✓ | Stock-Other | 0.08% | — | — | ||
| 41 | TCRX | Tscan Therapeutics Inc | Stock-Other | 0.05% | — | -86.74% | |
| 42 | SRZNW | Surrozen Inc-cw25 | Stock-Other | 0.05% | — | — | |
| 43 | ALGS | Aligos Therapeutics Inc | Stock-Other | 0.04% | — | -65.34% | |
| 44 | UPB | Upstream Bio Inc | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | APLSUSD | Apellis Pharmaceuticals Inc | — | NEW | New buy |
| 2 | JAZZ | Jazz Pharmaceuticals plc | — | NEW | New buy |
| 3 | ZYME | Zymeworks Inc | — | NEW | New buy |
| 4 | ANAB | Anaptysbio Inc | — | NEW | New buy |
| 5 | CRNX | Crinetics Pharmaceuticals In | — | NEW | New buy |
| 6 | PRTA | Prothena Corporation plc | — | NEW | New buy |
| 7 | SRPT | Sarepta Therapeutics Inc | — | NEW | New buy |
| 8 | XNCR | Xencor Inc | — | NEW | New buy |
| 9 | CRSP | CRISPR Therapeutics AG | — | NEW | New buy |
| 10 | QURE | uniQure N.V. | — | NEW | New buy |
| 11 | JANX | Janux Therapeutics Inc | — | NEW | New buy |
| 12 | IMNM | Immunome Inc | — | NEW | New buy |
| 13 | ETON | Eton Pharmaceuticals Inc | — | NEW | New buy |
| 14 | MDGL | Madrigal Pharmaceuticals Inc | — | NEW | New buy |
| 15 | ORIC | Oric Pharmaceuticals Inc | — | NEW | New buy |
| 16 | AKRO | Akero Therapeutics Inc | — | NEW | New buy |
| 17 | KURA | Kura Oncology Inc | — | NEW | New buy |
| 18 | TECX | Tectonic Therapeutic Inc | — | NEW | New buy |
| 19 | RNAGBP | Avidity Biosciences Inc | — | NEW | New buy |
| 20 | NGNE | Neurogene Inc | — | NEW | New buy |
| 21 | TNGX | Tango Therapeutics Inc | — | NEW | New buy |
| 22 | VYGR | Voyager Therapeutics Inc | — | NEW | New buy |
| 23 | BEAM | Beam Therapeutics Inc | — | NEW | New buy |
| 24 | MBX | Mbx Biosciences Inc | — | NEW | New buy |
| 25 | DNA | Ginkgo Bioworks Holdings Inc | — | NEW | New buy |
| 26 | REPL | Replimune Group Inc | — | NEW | New buy |
| 27 | BCYC | Bicycle Therapeutics Plc-adr | — | NEW | New buy |
| 28 | DAWNGBX | Day One Biopharmaceuticals I | — | NEW | New buy |
| 29 | ✓ | Verve Therapeutics Inc | — | NEW | New buy |
| 30 | ADAPY | Adaptimmune Therapeutics-adr | — | NEW | New buy |
| 31 | LKFT | Lakefront Biotherapeutic-adr | — | NEW | New buy |
| 32 | WHWK | Whitehawk Therapeutics Inc | — | NEW | New buy |
| 33 | ATRA | Atara Biotherapeutics Inc | — | NEW | New buy |
| 34 | SLDB | Solid Biosciences Inc | — | NEW | New buy |
| 35 | KROS | Keros Therapeutics Inc | — | NEW | New buy |
| 36 | NUVB-WS | Nuvation Bio Inc -cw27 | — | NEW | New buy |
| 37 | RLAY | Relay Therapeutics Inc | — | NEW | New buy |
| 38 | KLRS | Kalaris Therapeutics Inc | — | NEW | New buy |
| 39 | PRME | Prime Medicine Inc | — | NEW | New buy |
| 40 | ✓ | — | NEW | New buy | |
| 41 | TCRX | Tscan Therapeutics Inc | — | NEW | New buy |
| 42 | SRZNW | Surrozen Inc-cw25 | — | NEW | New buy |
| 43 | ALGS | Aligos Therapeutics Inc | — | NEW | New buy |
| 44 | UPB | Upstream Bio Inc | — | NEW | New buy |
According to official SEC Form 13F filings, EcoR1 Capital, LLC reported a total U.S. public equity portfolio value of $2.1B across 44 disclosed positions in Q1 2025.
During Q1 2025, EcoR1 Capital, LLC's top holdings by market value included APLSUSD (15.4%)、JAZZ (12.6%)、ZYME (12.2%). The largest single position, APLSUSD, represented 15.4% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
APLSUSD
市值: $260.2M
In Q1 2025, EcoR1 Capital, LLC made 44 total portfolio adjustments, initiating 44 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.